Monitor for selling stockholder sales under the shelf — any material volume could pressure the already-depressed $0.21 stock price. Watch for warrant exercises only if the stock rises above the weighted average exercise price of ~$0.28. The going-concern qualification and lack of revenue make any equity-linked financing a distress signal.
Price Chart
Executive Summary
CytoDyn filed an S-3 registration statement to register 794,972,289 shares of common stock for resale by selling stockholders, including 410,046,456 already-issued shares and 384,925,833 shares underlying warrants. The company will not receive proceeds from share sales but could receive up to ~$94.6 million if all warrants are exercised for cash. The filing signals massive potential overhang — the registered shares represent ~54% of the current 1.47B shares outstanding — and the auditor's report includes a going-concern qualification, indicating severe financial distress.
Key Facts
- S-3 registers 794,972,289 shares for resale: 410,046,456 issued shares + 384,925,833 warrant shares
- Shares outstanding as of Sept 24, 2026: 1,469,518,019; registered shares = ~54% dilution overhang
- Company receives no proceeds from share sales; up to ~$94.6M if all warrants exercised for cash
- Warrant exercise prices range from $0.09387 to $0.50 per share; weighted avg exercise price ~$0.28
- Stock closed at $0.21/share on Sept 24, 2026 — many warrants are out of the money
- Auditor's report on FY2026 financials includes a going-concern qualification
- Company is a clinical-stage biotech with no approved products; only drug candidate is leronlimab
- Selling stockholders include former director David F. Welch (2.6% holder), Thomas Hamilton (2.4%), and numerous retail investors
- Registration covers shares from private offerings, warrant exchanges, legal settlements, and backstop agreements dating back to 2011
- Company paid Paulson Investment Company ~$2.3M in cash fees as placement agent
Financial Impact
Potential warrant exercise proceeds up to ~$94.6M; registered shares represent ~54% of current outstanding shares at $0.21/share (~$167M market value at current price)
Risk Factors
- Massive dilution overhang of 795M shares (~54% of current float) could suppress stock price
- Going-concern qualification signals high risk of bankruptcy or need for dilutive financing
- No approved products or revenue; leronlimab still in Phase 2 trials with uncertain regulatory path
- Many warrants are out of the money (exercise prices up to $0.50 vs $0.21 stock price), limiting potential cash proceeds
- OTCQB listing limits institutional investor base and liquidity
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001175680-26-000024 |
| Document: ck0001175680-exfiling_fees.htm | 0001175680-26-000024 |
| Document: ck0001175680-ex5_1.htm | 0001175680-26-000024 |
| Document: ck0001175680-ex23_1.htm | 0001175680-26-000024 |
| Document: 0001175680-26-000024-index-headers.html | 0001175680-26-000024 |
| Document: 0001175680-26-000024-index.html | 0001175680-26-000024 |
| Document: 0001175680-26-000024.txt | 0001175680-26-000024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | DEFA14A | $0.2500 $0.2500 | · 0.00% | ▼ −0.53% | $0.2600 (+4.00%) |
Oct 19, 2026 6d ago | 8-K | $0.2500 $0.2500 | · 0.00% | ▼ −0.53% | $0.2600 (+4.00%) |
Oct 8, 2026 18d ago | EFFECT | $0.2000 $0.2000 | · 0.00% | ▲ +0.60% | $0.2600 (−30.00%) |
Oct 5, 2026 21d ago | EFFECT | $0.2000 $0.2000 | · 0.00% | ▲ +0.55% | $0.2600 (−30.00%) |
Oct 5, 2026 21d ago | EFFECT | $0.2000 $0.2000 | · 0.00% | ▲ +0.55% | $0.2600 (−30.00%) |
Sep 25, 2026 4w ago | S-3 | $0.2200 $0.2000 | ▲ +9.09% | ▲ +8.91% | $0.2600 (−18.18%) |
Mar 5, 2026 33w ago | 8-K | $0.2400 $0.2300 | ▲ +4.17% | ▲ +2.85% | $0.2600 (−8.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers